TL;DR:
- Turbine, a company specializing in cell simulations for biopharma R&D, has received €5.5 million from MassMutual Ventures (MMV) in its Series A funding round, bringing the total to €25.5 million.
- The investment adds U.S.-based investors to Turbine’s financing syndicate and enhances the company’s board with the addition of four independent directors.
- Turbine’s cutting-edge lab facilities in Budapest and collaboration with Cancer Research Horizons contribute to its recent momentum.
- The funding will be utilized to advance Turbine’s pipeline of simulation-guided programs and expand its biology simulation platform for partnerships.
- Turbine’s unique approach combines cell simulation and machine learning to uncover novel cancer therapies and identify patients who will benefit from them.
- The simulations enable the representation of patient populations previously inaccessible and conduct assays efficiently at scale.
- Turbine’s proprietary closed-loop learning process continually validates hypotheses, leading to a dynamic model of cancer biology.
- The company’s innovative engine uncovers novel targets, biomarkers, and drug combinations with high potential for patient populations with unmet needs.
- Turbine has the support of industry leaders such as Bayer and MSD, with multiple in vivo validated assets in its proprietary and partnered pipeline.
- The investment from MassMutual Ventures and the expertise of the board members validate Turbine’s potential to revolutionize biopharma R&D.
Main AI News:
In a significant development for the biopharmaceutical research and development (R&D) landscape, Turbine, a pioneering company utilizing cell simulations to revolutionize drug discovery and ensure tailored treatment for patients, has successfully secured a €5.5 million investment from MassMutual Ventures (MMV) in its recently concluded Series A funding round. With this latest infusion of capital, Turbine’s oversubscribed Series A round now totals €25.5 million, while also attracting additional U.S.-based investors to its esteemed group of funding partners. Alongside this financial achievement, Turbine has proudly announced the appointment of four independent directors to its distinguished board.
Today’s milestones serve to bolster Turbine’s recent surge of momentum, characterized by the establishment of state-of-the-art laboratory facilities in Budapest and a groundbreaking collaboration with Cancer Research Horizons. The fresh funding will be instrumental in advancing Turbine’s internal pipeline of simulation-guided programs, as well as scaling its cutting-edge biology simulation platform to accommodate further strategic partnerships.
“At Turbine, we are transcending the limitations of conventional drug discovery approaches by seamlessly integrating cell simulation and machine learning, thereby unearthing innovative cancer therapies and identifying the patients most likely to benefit from them,” expressed Anvesh Ramineni, Managing Partner at MMV. “Turbine’s unparalleled approach possesses immense potential in guiding biopharma R&D towards uncharted territories, leveraging actionable insights gleaned from our profound expertise in simulating biological mechanisms. We eagerly anticipate collaborating with Turbine to unlock its full potential and spearhead transformative advancements.”
Since its inception in 2015, Turbine has forged ahead with simulations that bridge the gaps left by existing biological models, enabling the representation of patient populations that were previously unattainable. Moreover, Turbine’s simulations possess the capacity to conduct assays on a scale and with a level of efficiency that would be impractical using traditional methods. By employing a proprietary closed-loop learning process, Turbine’s in vitro and in vivo assays systematically validate promising hypotheses, leading to a perpetually evolving model of cancer biology.
The outcome is an innovation engine that continuously reveals fresh targets, biomarkers, and drug combinations, all of which undergo rigorous experimental validation and often eludes detection through conventional means, including CRISPR. Clinically, these identified targets are associated with patient populations facing high unmet medical needs. Backed by esteemed companies such as Bayer and MSD (Merck & Co., Inc., Rahway NJ, USA), Turbine boasts a comprehensive portfolio of in vivo validated novel assets, both proprietary and collaborative.
“The support from MassMutual Ventures, a preeminent global investor with deep-rooted ties to the U.S. market, combined with the unwavering enthusiasm of the renowned experts joining our board, unequivocally validates Turbine’s boundless potential,” declared Szabolcs Nagy, Chief Executive Officer and Co-Founder of Turbine. “These exceptional individuals have personally spearheaded leading technology platforms that have propelled drug development on a global scale. Their unequivocal support signifies the distinctiveness of our platform and its capacity to unlock genuinely novel therapies for currently underserved patient populations, all achieved through an efficient, simulation-guided development approach. With the newfound funding and the addition of esteemed board members, we are poised to accelerate the validation of our approach by advancing multiple programs and partnerships towards the ultimate litmus test of any biopharmaceutical technology platform – human clinical trials.”
Conclusion:
Turbine’s successful funding round and strategic partnerships, combined with its unique approach to cell simulation and machine learning, position the company as a leader in uncovering novel cancer therapies. With the support of investors and industry experts, Turbine is poised to drive significant advancements in biopharmaceutical research and development, offering potential breakthroughs for underserved patient populations. This development signals a positive outlook for the market, showcasing the growing importance of simulation-guided approaches and their potential impact on drug discovery and personalized medicine.
